Document:

EX-10.8

 Exhibit 10.8 

PHARMEDIUM HEALTHCARE CORPORATION 

c/o JVC Management LLC 
 1059 Elm
Ridge Drive 
 Glencoe, Illinois 60022 

(847) 242-9160 
 August 4,
2003 
 Richard Kruzynski 
 4454 Kettering Drive 

Long Grove, Illinois 60047 
 Dear Rich: 

We are very pleased to offer you the position of President of PharMedium Healthcare Corporation (“PHC”) (contingent upon delivery to PHC of a
complete copy of your agreement with Baxter Healthcare Corporation, and your signing PHC’s standard Employment Agreement), reporting to PHC’s Chairman and Chief Executive Officer. Your leadership, experience, and commitment will be of
great value to our team and to the company. The effective date of your employment will be on the date of close of the acquisition of Baxter’s COMPASS Business unit (the “Closing Date”), now targeted on August 4, 2003. Your annual
starting salary will be the same as your current annual salary from Baxter, $161,099.21. In addition, you will be eligible for a Management Incentive Compensation Plan (“MICP”) bonus from PHC targeted at your current percentage
(30%) of your base salary. Your MICP target bonus amount from PHC for 2003 will be equal to your original MICP target bonus amount for 2003 (30%) as established by Baxter, prorated for the balance of calendar year 2003 with payout based on
individual and PHC performance targets. To be eligible for a bonus, you must be employed through the applicable payout date (upon completion of audited financials). In addition, you will be eligible for options under PHC’s Management stock
option program, with plan documents and information to be provided at a later date. Immediately after the Closing Date, PHC will have 850,000 shares of common stock issued and outstanding, and will have reserved 150,000 shares of common stock for
the issuance of stock option grants. You will be granted options for 35,000 shares of common stock on terms no less favorable than the terms on which options are then being granted to other senior executives. 

You will be eligible for the PHC standard and executive benefits program, including four (4) weeks vacation. As you know, the specifics of these programs
are still under development. Details will be provided at a later date. Once established, these benefits programs are subject to change at any time at the sole discretion of PHC. In addition, if PHC shall terminate your employment without cause
(cause for this purpose means gross negligence, breach of any material contract obligation to PHC or any of its subsidiaries, 

  
 Mr. Richard Kruzynski 

August 4, 2003 
 Page 2 

 

 willful misconduct or dishonesty, violation of company policy, or conviction of a felony) or if you shall
voluntarily terminate your employment within thirty (30) days after PHC shall have reduced your cash compensation (salary and target bonus) or moved your office to any location more than fifty (50) miles from your current residence, then
you will be entitled to a continuation of your cash compensation (salary and target bonus) until the later of (i) eighteen (18) months from the Closing Date, or (ii) the date which is twelve (12) months following such termination
of employment. This offer expires at 2.00 Central Time today. Finally, please understand that all PHC employees will be subject to the terms contained in the PHC Employee Manual, which will be provided to you upon completion. 

P1ease note this letter does not constitute an agreement or contract for employment for any specific period of time or definite duration. Your employment with
PHC is “at-will”, and either you or PHC may terminate your employment at any time, with or without cause or notice, except as otherwise provided by law. 

If you agree with the terms of this letter, please sign and fax it back to PHC confidentially at 847-242-9160 at your earliest convenience. 

Again, it is a great to have you as a member of our team! We know you will make outstanding contributions! 

 

	
	Sincerely,
	
	/s/ David N. Jonas
	 David N. Jonas
 Chairman and Chief Executive
Officer

  

	
	 ACCEPTED AND AGREED
 this 4th day of August,
2003

	
	/s/ Richard Kruzynski
	Richard KruzynskiEX-10.9

 Exhibit 10.9 

EMPLOYMENT AGREEMENT 
 (NOTE:
BEFORE SIGNING, PROSPECTIVE EMPLOYEES SHOULD READ THE FOLLOWING AGREEMENT IN ITS ENTIRETY, MAKE CERTAIN THAT THEY UNDERSTAND IT, AND IF DESIRED, REVIEW IT WITH THEIR ATTORNEYS AND ADVISORS.) 

In consideration of my employment and the compensation to be paid to me by PharMedium Healthcare Corporation, PharMedium Services, LLC or any of its
affiliated companies, and their respective successors or assigns (collectively, “PharMedium”), I agree as follows: 
  

	1.	For purposes of this agreement: 

  

	 	(a)	“Competing Products” means products, processes, or services of any person or organization other than PharMedium, in existence or under development, which are substantially the same, may be substituted for, or
applied to substantially the same end use as the products, processes or services with which I work during the time of my employment with PharMedium or about which I acquire Confidential Information through my work with PharMedium. 

 

	 	(b)	“Competing Organization” means persons or organizations, including myself, engaged in, or about to become engaged in, research or development, production, distribution, marketing, providing or selling of a
Competing Product. 

  

	 	(c)	“Confidential Information” means information relating to the present or planned business of PharMedium which has not been released publicly by authorized representatives of PharMedium. I understand that
Confidential Information may include, for example, Trade Secrets, Inventions, know-how and products, customer patient, supplier and competitor information, sales, pricing, cost and financial data, research, development, marketing and sales programs
and strategies, manufacturing, marketing and service techniques, processes and practices, and regulatory strategies. I understand further that Confidential Information also includes all information received by PharMedium under an obligation of
confidentiality to a third party. 

  

	 	(d)	“Invention” means procedures, systems, machines, methods, processes, uses, apparatuses, compositions of matter, designs or configurations, computer programs of any kind, or any improvements of the foregoing,
discovered, conceived, reduced to practice, developed, made, or produced, and shall not be limited to the meaning of “Invention” under the United States patent laws. 

	 	(e)	“Items” include documents, reports, drawings, photographs, designs, specifications, formulae, plans, samples, research or development information, prototypes, tools, equipment, proposals, marketing or sales
plans, customer information, customer lists, patient information, regulatory files, financial data, costs, pricing information, supplier information, written, printed or graphic matter, or other information and materials that concern
PharMedium’s business that come into my possession or about which I have knowledge by reason of my employment. 

  

	 	(f)	“Trade Secrets” include all information known to PharMedium encompassed in any Item, or in any manufacturing process, method of production, concept or idea, to the extent that such information has not been
released publicly by duly authorized representatives of PharMedium. 

  

	2.	I will exert my best efforts in the performance of my duties as an employee of PharMedium and will remain loyal to PharMedium during the term of my employment. I am not presently engaged in, nor shall I, during the term
of my employment with PharMedium, enter into any employment or agency relationship with any third party whose interests might conflict with those of PharMedium. I do not presently, nor shall I, during the term of my employment with PharMedium,
possess any significant interest, directly, through my family, or through organizations or trusts controlled by me, in any third party whose interest might conflict with those of PharMedium. 

 

	3.	Each Item and all Confidential Information that comes into my possession by reason of my employment are the property of PharMedium and shall not be used by me in any way except in the course of my employment by, and for
the benefit of PharMedium. I will not remove any Item from premises owned or leased by PharMedium except as my duties shall require, and upon termination of employment, all Items will be turned over to my supervisor at PharMedium. 

 

	4.	I will preserve as confidential all Confidential Information that has been or may be obtained by me. I will not, without written authority from PharMedium, use for my own benefit or purposes, or disclose to others,
either during my employment or thereafter, except as required by my employment with PharMedium, any Confidential Information or any copy or notes made from any item embodying Confidential Information. I understand that my obligations with respect to
Confidential Information shall continue even after termination of my employment with PharMedium. These restrictions concerning use and disclosure of Confidential Information shall not apply to information which is or becomes publicly known by lawful
means, or comes into my possession from sources not under any obligation or confidentiality to PharMedium. 

  
 2 

 (NOTE: PHARMEDIUM WILL SEEK JUDICIAL ENFORCEMENT OF ITS RIGHT TO PROTECT CONFIDENTIAL INFORMATION AND TRADE
SECRETS, AND SHALL PURSUE ALL LEGAL REMEDIES UP TO AND INCLUDING PROHIBITION OF COMPETITIVE EMPLOYMENT OPPORTUNITIES WHICH WOULD INVOLVE THE DISCLOSURE OR USE OF THIS INFORMATION. UPON LEAVING PAHARMEDIUM YOUR ABILITY TO ACCEPT EMPLOYMENT WITH
COMPETING ORGANIZATIONS WITH ADMIXTURE COMPOUNDING PROGRAMS WILL BE LIMITED.) 
  

	5.	I understand that any entrusting of Confidential Information to me by PharMedium is done in reliance on a confidential relationship arising out of my employment with PharMedium. I further understand that Confidential
Information that I may acquire or to which I may have access, especially with regard to research and development projects and findings, formulae, designs, formulation, processes, the identity of suppliers, customers and patients, methods of
manufacturer, and cost and pricing data is of great value to PharMedium. In consequence of which entrusting and such consideration, I will not render services, directly or indirectly, for a period of one year after termination of my employment with
PharMedium to any Competing Organization in connection with any Competing Product within such geographic limits as PharMedium and such Competing Organization are, or would be, in actual competition when such rendering of services might potentially
involve the disclosure or use of Confidential Information or Trade Secrets. I understand that services rendered to such Competing Organization in an executive, scientific, administrative, or consulting capacity in connection with Competing Products
are in support of actual competition in various geographic areas and thus fall within the prohibition of this agreement regardless of where such services physically are rendered. Further, if, at any time during the last two years of my employment
with PharMedium I have been employed as a sales representative, I will not render services, directly or indirectly, for a period of one year after termination of my employment with PharMedium to any Competing Organization in connection with the
sale, merchandising, or promotion of Competing Products to any customer of PharMedium in the territories assigned to me by PharMedium within the last 12 months, or with respect to which I acquired Confidential Information. 

 

	6.	I understand that following my employment with PharMedium I will make every effort to contact PharMedium’s Chief Executive Officer if I am served with a subpoena or other legal process asking for a deposition,
testimony or other statement, or other potential evidence to be used in connection with any lawsuit to which PharMedium is a party. 

  
 3 

	7.	All Inventions related to the present or planned business of PharMedium, which are conceived or reduced to practice by me, either alone or with others, during the period of my employment or during a period of one
hundred twenty (120) days after termination of such employment, whether or not done during my regular working hours, are the sole property of PharMedium. The provisions of this paragraph shall not apply to an invention for which no equipment,
supplies, facilities or trade secret information of PharMedium was used and which was developed entirely on my own time, unless (a) the invention relates (i) to the business of PharMedium, or (ii) to my actual or demonstrably
anticipated research or development for PharMedium, or (b) the invention results from any work performed by me for PharMedium. 

  

	8.	I will disclose promptly and in writing to PharMedium, through my supervisor, all Inventions which are covered by this agreement, and I agree to assign to PharMedium or its nominee all my right, title, and interest in
and to such Inventions. I agree not to disclose any of these Inventions to others, without the express consent of PharMedium, except as required by my employment. 

 

	9.      (a)	I will, at any time during or after my employment, on request of PharMedium, execute specific assignment documents in favor of PharMedium or its nominee of my interest in and to any of the Inventions covered by this
agreement, as well as execute all papers, render all assistance, and perform all lawful acts which PharMedium considers necessary or advisable for the preparation, filing, prosecution, issuance, procurement, maintenance or enforcement of patent
applications and patents of the United States and foreign countries for these Inventions, and for the transfer of any interest I may have therein. I will execute any and all papers and documents required to vest title in PharMedium or its nominee in
the above Inventions, patent applications, and interests. 

  

	           (b)	I understand that if I am not employed by PharMedium at the time I am requested to execute any document under paragraph 9(a), I shall receive fifty dollars ($50.00) for the execution of each document, and one hundred
fifty dollars ($150.00) per day of each day or portion thereof spent at the request of PharMedium in the performance of acts pursuant to paragraph 9(a), plus reimbursement for any out-of-pocket expenses incurred by me at PharMedium’s
request in such performance. 

  

	           (c)	I further understand that the absence of a request by PharMedium for information, or for the making of an oath, or for the execution of any document, shall in no way be construed to constitute a waiver of
PharMedium’s rights under this agreement. 

  
 4 

	10.	I have disclosed to PharMedium all continuing obligations which I have with respect to the assignment of inventions to any previous employers, and I claim no previous unpatented Inventions as my own, except for those
which have been reduced to practice and which are shown on a schedule, if any, attracted to this agreement. I understand that PharMedium does not seek any confidential information which I may have acquired from a previous employer, and I will not
disclose any such information to PharMedium. 

  

	11.	All writings and other works which may be copyrighted (including computer programs) which are related to the present or planned business of PharMedium and are prepared by me during my employment by PharMedium shall be,
to the extent permitted by law, works made for hire, and the authorship and copyright of the work shall be in PharMedium’s name. To the extent that such writings and works are not works for hire, I agree to the waiver of “moral
rights” in such writings and works, and I hereby assign to PharMedium all my right, title and interest in and to such writings and works, including copyright. 

 

	12.	I will permit PharMedium and its agents to use and distribute any pictorial images which are taken of me during my employment by PharMedium as often as desired for any lawful purpose. I waive all rights of prior
inspection or approval and release PharMedium and its agents from any and all claims or demands which I may have on account of the lawful use or publication of such pictorial images. 

 

	13.	I understand and agree that this agreement is not a guarantee of continued employment or rate of compensation for any period. My employment is at will. This means I am free to terminate my employment at any time, for
any reason, and that PharMedium retains the same rights. 

  

	14.	I understand that I may be asked to submit to drug testing as a condition of employment or continued employment and consent to such testing as determined by PharMedium to be appropriate. 

 

	15.	The obligations which I have undertaken in paragraphs 3, 4, 5, 6, 7, 8, 9, 11 and 12 shall survive the termination of my employment by PharMedium. 

 

	16.	PharMedium has a right to make and enforce any other rules and regulations not contrary to this agreement which will also govern my employment. 

 

	17.	The provisions of the agreement shall be severable, and in the event that any provision of it is found by any court to be unenforceable, in whole or in part, the remainder of this agreement shall nevertheless be
enforceable and binding on the parties. 

  
 5 

	18.	I agree that, to promote uniformity in the interpretation of this and similar agreements, this agreement shall be governed by the laws of Illinois for contracts made within that state. I further agree that this
agreement sets forth the entire employment agreement between PharMedium and myself, and shall not be amended or added to except in writing signed by PharMedium and me. I understand that PharMedium may, at any time and without further action by me,
assign this agreement to any of its affiliated companies with which I may be employed. In the event of such an assignment, the assignee company shall succeed to all the rights held by PharMedium under this agreement. 

Date: August 4, 2003 
  

	
	EMPLOYEE
	
	/s/ Richard J. Kruzynski
	Signature
	
	Richard J. Kruzynski
	Print Name

  
 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}]]